Selling to KEMSA: A Legal Guide to Kenya’s Pharmaceutical Procurement Process

A pharmaceutical supplier navigating KEMSA procurement for the first time is often surprised to learn that responding to an open tender notice is not, on its own, enough. Selling to KEMSA runs through two sequential gates, a periodic prequalification exercise and then a restricted tendering process open only to suppliers already inside that pool, anchored throughout to KEMSA’s own regulatory quality documentation.

The Statutory Framework Behind KEMSA Procurement

The KEMSA Act 2013 establishes KEMSA as a body corporate and, under section 4, mandates that public health facilities obtain drugs and medical supplies from KEMSA only where those products are duly registered with the Pharmacy and Poisons Board and meet applicable quality and efficacy standards; breach of this requirement carries a fine of up to KES 2 million or imprisonment of up to five years. Section 19 requires KEMSA to apply sound commercial principles in its procurement, storage, and distribution functions. As a state corporation, KEMSA’s actual procurement process is governed by the Public Procurement and Asset Disposal Act 2015, whose definition of a public entity expressly captures a state corporation within the meaning of the State Corporations Act. That Act sets out several procurement methods, with open tender as the default approach, alongside restricted tendering limited to prequalified suppliers, direct procurement in narrow circumstances, and framework agreements for recurring supply needs.

Prequalification Comes First, and It Runs on a Cycle

The Public Procurement and Asset Disposal Act defines prequalification as the procedure used to shortlist qualified tenderers before an invitation to tender is issued, and requires procuring entities to maintain and periodically update a supplier register. The 2020 Regulations made under the Act require that register to be updated every six months and put through fresh registration every two years, a cadence that matches KEMSA’s own practice: its most recent published pharmaceutical prequalification exercise, tender KEMSA-PREQ-D-2022/2024, governed supplier registration for that two-year cycle, and KEMSA’s own site has since shown registration for the following cycle as closed to new entrants outside its window. A supplier should check KEMSA’s current tenders page directly for the live prequalification document rather than relying on the specific dates of the 2022 to 2024 cycle, since the underlying requirements recur but the exact document and window change with each cycle.

What KEMSA’s Own Prequalification Document Actually Requires

KEMSA’s published pharmaceutical prequalification tender sets out mandatory preliminary documents common to public procurement generally: a certificate of incorporation, CR12 company particulars, a current KRA tax compliance certificate, a signed submission letter, and three years of certified financial statements, alongside evidence of at least three comparable pharmaceutical supply contracts completed in the preceding three years. An applicant must not appear on the Public Procurement Regulatory Authority’s debarred-supplier list, a status that under section 41 of the Act follows from grounds including a prior procurement offence, contract breach or poor performance, false qualification claims, tax default, or corrupt or fraudulent practice, and carries a minimum three-year debarment period. Beyond these general requirements, the pharmaceutical-specific documentation is where KEMSA’s process diverges from ordinary public procurement: a current Good Manufacturing Practice certificate from an independent body or a Market Authorization from the Pharmacy and Poisons Board, a PPB product registration certificate, a current manufacturing licence, and, for local applicants, a wholesale dealer’s licence and a superintendent pharmacist’s practising licence. A manufacturer supplying through an agent must also provide a manufacturer’s authorisation letter addressed specifically to KEMSA and specific to that prequalification round. Evaluation proceeds in three stages: a disqualifying preliminary document check, a technical documentation and certification review, and a technical product review covering physical, packaging, and labelling compliance on a pass or fail basis.

What Happens After Prequalification, and What Doesn’t Change

Once inside KEMSA’s prequalified supplier pool, subsequent supply opportunities are run as restricted tenders under section 102 of the Public Procurement and Asset Disposal Act, meaning only prequalified suppliers are invited to bid on individual supply contracts or framework call-offs; a supplier who has not gone through prequalification cannot simply respond to an individual tender notice for a pharmaceutical supply contract. On payment, an issue this firm has covered separately, KEMSA’s reimbursement delays of up to 18 months on delivered orders remain a live commercial risk that prequalification and certification do not address; a supplier should model that timing risk into its pricing and cash flow planning independently of the legal requirements for entering KEMSA’s supplier pool in the first place.

What This Means for a Prospective KEMSA Supplier

A pharmaceutical company planning to sell to KEMSA should treat prequalification as the gating first step, confirm the current prequalification document directly on KEMSA’s own tenders page rather than relying on a prior cycle’s dates, assemble the pharmaceutical-specific quality documentation, GMP certification, PPB registration, and manufacturing licensing, well ahead of a submission deadline, and separately budget for the reimbursement-timing risk that prequalification itself does not resolve.